Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies

This is the authors' abstract. We don't add key points for this paper.

Treatment with immune checkpoint inhibitors (ICIs), such as antiprogrammed death-1 (PD-1), antiprogrammed-death ligand-1 (PD-L1), and anticytotoxic T-lymphocyte antigen-4 monoclonal antibodies, have dramatically changed the treatment landscape for a wide range of malignancies ([1][1] , [2][2]). ICIs